Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 25.73M | 35.27M | 26.98M | 14.46M | 11.70M | 10.39M |
Gross Profit | 20.17M | 28.11M | 20.51M | 10.78M | -33.18M | -22.76M |
EBITDA | -219.83M | -164.89M | -183.40M | -112.96M | -64.08M | -50.39M |
Net Income | -203.27M | -169.03M | -180.66M | -112.72M | -66.82M | -51.01M |
Balance Sheet | ||||||
Total Assets | 883.89M | 956.87M | 595.34M | 410.61M | 479.79M | 161.15M |
Cash, Cash Equivalents and Short-Term Investments | 792.97M | 879.52M | 526.42M | 339.15M | 438.68M | 135.99M |
Total Debt | 8.32M | 9.49M | 44.96M | 44.33M | 44.34M | 15.78M |
Total Liabilities | 143.56M | 163.81M | 224.41M | 139.83M | 133.54M | 65.69M |
Stockholders Equity | 740.33M | 793.06M | 370.93M | 270.78M | 346.25M | 95.46M |
Cash Flow | ||||||
Free Cash Flow | -182.13M | -165.96M | -63.56M | -105.10M | -16.82M | -18.99M |
Operating Cash Flow | -180.23M | -164.72M | -60.63M | -86.11M | -14.79M | -17.79M |
Investing Cash Flow | -1.83M | -1.24M | -2.93M | -18.99M | -2.03M | -1.20M |
Financing Cash Flow | 518.01M | 519.75M | 250.03M | 6.69M | 320.73M | 62.84M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
63 Neutral | $603.54M | ― | -216.14% | ― | 203.23% | -80.71% | |
57 Neutral | $626.14M | ― | -452.20% | ― | 8.98% | 6.32% | |
52 Neutral | $7.53B | 0.32 | -61.76% | 2.28% | 16.60% | 1.56% | |
48 Neutral | $514.17M | ― | -37.13% | ― | -38.14% | 29.69% | |
47 Neutral | $789.47M | ― | -241.16% | ― | 6.30% | 29.17% | |
47 Neutral | $507.33M | ― | -41.84% | ― | ― | 3.95% | |
40 Underperform | $482.39M | ― | ― | -25.10% | -7.06% |
On June 17, 2025, Bicycle Therapeutics held its annual general meeting where all proposals, including director re-elections and auditor appointments, were approved by shareholders. The meeting saw high shareholder participation, with approximately 98.63% of shares represented, reflecting strong support for the company’s governance and strategic direction.
The most recent analyst rating on (BCYC) stock is a Buy with a $42.00 price target. To see the full list of analyst forecasts on Bicycle Therapeutics stock, see the BCYC Stock Forecast page.
On April 29, 2025, Bicycle Therapeutics announced additional human radiopharmaceutical imaging data for MT1-MMP at the AACR Annual Meeting 2025, demonstrating the potential of MT1-MMP as a novel cancer target. The data, involving 12 patients with various solid tumors, highlighted the efficacy of Bicycle® Radioconjugates (BRC®) in radiopharmaceutical imaging, showing promising results in tumor targeting and tracer uptake. The company plans to advance its radiopharmaceutical pipeline with initial human imaging data for a second target, EphA2, expected later in 2025, and company-sponsored clinical trials planned for 2026.